ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes
4.6.2021 15:00:00 EEST | Business Wire | Press release
Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data from the national FLEX registry that identify differences in tumor biology between ethnic groups that can lead to meaningful treatment decisions, reinforcing the need for appropriate representation of diverse patient populations in breast cancer studies.
A major theme of this year’s ASCO meeting centers around disparities in care and outcomes, which Agendia’s FLEX study aims to combat by prospectively enrolling 30,000 patients from various ethnicities, ages and demographic groups representative of the total breast cancer population. The data presentation from this study, “Disparities within Luminal breast cancer: clinical and molecular features of African American and non-Hispanic White patients,” delivered by first author of the study Kent Hoskins, MD, Co-Leader of the Breast Cancer Research Group and Director of Cancer Genetics at the University of Illinois Cancer Center, details significant biological differences in luminal breast tumors from African American and non-Hispanic White women, suggesting that shared adverse socioeconomic exposures and/or genetic ancestry may be driving disproportionately aggressive tumor biology in African American women. This finding further underscores the need for inclusion of diverse patient groups in clinical trials to ensure equity in drug development.
“The data presented at ASCO 2021 show significant transcriptomic differences between Luminal tumors from African American and non-Hispanic White patients, seen even more starkly as our study controlled for age, obesity, and genomic classification,” said Dr. Hoskins. “The data show ER+ breast cancers in African American women more often had upregulation of the mTOR pathway and cell cycle genes, which require different treatment approaches than other ER+ breast cancers. These data tell us that we desperately need proper representation of diverse populations in clinical trials, and future studies focused on the efficacy of these agents specifically in African American women with breast cancer, so that all patients can benefit from precision medicine, tailored to them, and accounting for their ancestry and genomic profiles.”
Additional data from Agendia regarding breast cancer in African American women was shared in an abstract titled “Genomic risk classification by the 70-gene signature and 21-gene assay in African American, early-stage breast cancer patients.” This study was triggered by recent research showing less accurate prognostic performance of OncotypeDX in African American women with early stage breast cancer. The abstract compared MammaPrint and OncotypeDX results in a cohort of African American women with ER+ breast cancer, and observed an overall discordance of 51% between the two tests in African American patients; notably, of tumors with a TAILORx intermediate risk score (11-25), 61% were classified as MammaPrint High Risk. Combined with previously published data in African American patients, 57% of OncotypeDX low risk score tumors are re-classified as MammaPrint High Risk, suggesting that OncotypeDX results could be less accurate in African American patients.
In addition, recent data indicate that African American patients who receive a low or intermediate OncotypeDX risk score have higher recurrence rates and lower survival than Caucasian patients with early stage breast cancer with the same risk score, a difference that can have meaningful clinical implications and requires further investigation.1
“It is essential that genomic tests either work consistently across diverse groups of patients, or have the ability to be calibrated to do so,” said Patricia Robinson, MD, Associate Professor of Hematology and Oncology at Loyola University Medical Center, and Assistant Dean of Diversity, Equity and Inclusion at the Strich School of Medicine, “We cannot be using genomic tests that work for some people and not others, or accepting that the tests, which offer such crucial information, work better for some than for others. While the clinical evaluation of the discrepancy between OncotypeDX and MammaPrint may be ongoing, this data still captures the diversity of pathways driving tumor metastasis, and reinforces the importance of proper representation in trials and in test development and optimization.”
Agendia’s large-scale, prospective FLEX registry continues to highlight data from real-world practices in one of the most flexible and inclusive studies in breast cancer research to date, playing an important part in the company’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
1 Hoskins, Kent F., et al. “Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer–Specific Mortality Among US Women.” JAMA Oncology, vol. 7, no. 3, 2021, p. 370., doi:10.1001/jamaoncol.2020.7320.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005255/en/
Contact information
Media
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release
Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 14:00:00 EET | Press release
The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “For generations, Bacardi has had a front-row seat to what’s next in drinks. By combining insights from bar teams, leading venues
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release
Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release
SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release
Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
